BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, selective inhibition of BCL‐2, aided by TKI‐mediated MCL‐1 and BCL‐XL inhibition, markedly decreased leukemic Lin(−)Sca‐1(+)cKit(+) cell numbers and prolonged survival time in a murine CML model.17